ÂÜÀòÂÒÂ×

Ulrike Rauh (Sack) serves as the Chief Development Officer at PROSION Therapeutics since January 2024 and has been a German Accelerator Mentor at Start2 Group since August 2021, assisting early start-up companies in various strategic areas. Previously, Ulrike held several prominent positions, including CEO/CSO and Vice President of Oncology at Trueline Therapeutics from November 2021 to May 2024, and Senior Consultant for Oncology at Anji Pharma from November 2021 to January 2023. Ulrike's extensive background includes roles at Bayer Pharmaceuticals as Senior Global Portfolio Manager and Clinical Project Manager, and postdoctoral research at Max Delbrueck Center. Academic qualifications comprise a PhD in Molecular Medicine from Humboldt-Universität zu Berlin, an MSc in Genetical Manipulation and Molecular Cell Biology from the University of Sussex, and a BSc in Biological Sciences from the University of Konstanz.